Device Trial Radar · NCT02497950
HeartMate 3 ELEVATE™ Registry
Last checked: Nov 20, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
540
Actual
Start
Oct 13, 2015
Primary completion
Feb 2019
Study completion Feb 28, 2022
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- Collaborators
- Thoratec Europe Ltd; Thoratec Corporation
- First posted
- Jul 15, 2015
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate real-world experience of HeartMate 3 (HM3) in post-approval setting.
Conditions
- Heart Failure
- Cardiovascular Disease
- Ventricular Dysfunction
Interventions
HeartMate 3Device
Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3
Primary outcomes
What the sponsor says the trial is designed to measure.
- SurvivalTime frame: Up to 5 Years post-implant
Locations
26 sites in 11 countries. Site status is shown where the registry gives one.
AJH - Wien
Vienna, Austria
Institute for Clinical and Experimental Medicine (IKEM)
Prague, Czechia
Rigshospitalet Copenhagen
Copenhagen, Denmark
23 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.